Dr. Clive Dix has stepped into the Chief Executive Officer role of our client, C4X Discovery. Clive has been Non-Executive Chairman of C4X since October 2014 until then CEO, Piers Morgan, stepped down to pursue opportunities outside of the company in November 2015. Instead of reappointing, Clive decided to take on the role of CEO himself, with non-executive Sam Williams taking on an interim Chairman position.
When asked about his decision to take on an executive role, Dr Dix said;
“Having seen from an executive position the potential of the platform to generate entirely new compounds against high-value therapeutic targets more rapidly and efficiently than any technology I’ve come across before and having witnessed the interest we’re receiving in C4X Discovery, I am delighted to take the helm on a full-time basis. I have never been more excited by a company than this one”.
Dr Clive Dix is widely recognised as one of the leading figures in the UK biotechnology sector and was awarded the BioIndustry Association (BIA) Lifetime Achievement Award in January this year.
C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. A hybrid business formed in 2008 of wholly-owned programmes and partnerships with pharma, biotech and academics, the Manchester-based company have grown rapidly over the last 18 months with expansion reaching their new London location.
We at summ.it are excited to be supporting C4X Discovery and look forward to long-lasting relationship with them.